Pfizer committed $150 million upfront in a deal to secure an oral small‑molecule GLP‑1 candidate from a Fosun subsidiary as part of a renewed push into obesity therapies. The move follows Pfizer’s broader buying and licensing activity in obesity and signals the company’s continued hunt for an oral alternative to peptide GLP‑1s. Pfizer CFO commentary at investor conferences confirmed the company’s appetite for oral GLP‑1s, and this upfront payment positions Pfizer to compete in an increasingly crowded oral obesity space alongside oral entrants from Structure, Novo Nordisk and Eli Lilly. The transaction highlights big‑pharma strategies to augment in‑house R&D with external small‑molecule programs that could offer different manufacturing and distribution profiles compared with injectable peptides.